NYSE$PEN

Penumbra Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Penumbra reported first quarter results with revenue increase and strong thrombectomy growth.

Penumbra, Inc. reported a 15.4% increase in revenue to $278.7 million for Q1 2024, driven by a 35.2% increase in U.S. thrombectomy revenue. The company's adjusted EBITDA was $37.6 million with a margin of 13.5%.

  • Revenue increased by 15.4% to $278.7 million in Q1 2024.
  • U.S. thrombectomy revenue grew by 35.2% in Q1 2024.
  • Non-GAAP income from operations was $19.3 million in Q1 2024.
  • Adjusted EBITDA reached $37.6 million with a 13.5% margin in Q1 2024.

Headline financials

Total Revenue

$279M

Previous: $241M+15.4%
EPS (adj)

$0.41

Previous: $0.23+78.3%
Capital Expenditures

-$5.82M

Previous: -$3.89M-49.6%
Free Cash Flow

$5.18M

Previous: $4.67M+10.9%
Net Income

$11M

Previous: $8.56M+28.5%
Operating Income

$12.1M

Previous: $8.01M+51.1%
Gross Profit

$181M

Previous: $151M+19.9%
Cash & Equivalents

$223M

Previous: $94.7M+135.6%
Total Assets

$1.58B

Previous: $1.4B+13.2%
R&D Expense

$24.6M

No prior period
Stock-Based Comp

$13.6M

Previous: $12.8M+6.3%

Revenue & EPS history

Penumbra · Revenue · Quarterly

$279M

Q1 2024+15.4%vs Q1 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Penumbra · $271M total across 2 segments · Q3 2023

  • Thrombectomy
    $179M
  • Embolization and Access
    $91.9M

Forward guidance

Penumbra reiterates its full year 2024 revenue guidance to be in the range of $1,230.0 million to $1,270.0 million, representing year over year growth of 16% to 20%. The company also continues to project the U.S. thrombectomy franchise will grow 27% to 30% year-over-year.

Tailwinds

  • Total revenue for 2024 expected to be between $1,230.0 million and $1,270.0 million.
  • U.S. thrombectomy franchise projected to grow 27% to 30% year-over-year.
  • Gross margin expansion expected in the range of 100 to 150 basis points in 2024.
  • Total non-GAAP operating margin expansion projected in the range of 100 to 200 basis points in 2024.
  • Strong growth trends in the first quarter reinforce total revenue and U.S. thrombectomy revenue guidance ranges.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

+2.0%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+1.9%

Avg return

30 days after

57%

28 / 49 earnings

Positive

+23.4%

Q4 2014

Best reaction

-15.8%

Q2 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%-0.7%-1.1%
Q4 2025+0.9%+0.4%-1.1%
Q3 2025+17.1%+24.0%+33.3%
Q1 2025+7.0%+6.5%-3.7%
Q4 2024+12.0%+6.1%+3.4%
Q3 2024+9.2%+9.5%+16.5%
Q2 2024-6.3%-1.6%+13.5%
Q1 2024-4.0%+0.3%-7.2%
Q4 2023-7.7%-10.1%-13.0%
Q3 2023+2.0%+1.3%+17.4%
Q2 2023-11.2%-16.8%-12.8%
Q1 2023+5.5%+8.6%+10.1%
Q4 2022+2.3%-0.5%+5.1%
Q3 2022+3.0%+12.0%+34.0%
Q2 2022+13.7%+8.7%+12.5%
Q1 2022-3.6%-15.3%-17.6%
Q4 2021-3.4%+5.6%-2.6%
Q3 2021+3.0%-1.8%-14.8%
Q2 2021-2.1%-2.4%+3.0%
Q1 2021-8.3%-8.9%-13.9%
Q4 2020+3.2%+1.6%-3.4%
Q3 2020+10.6%+3.9%-5.1%
Q2 2020+2.5%+5.5%-3.5%
Q1 2020+1.4%+2.4%+1.4%
Q4 2019-6.8%-10.0%-13.7%
Q3 2019-0.8%+0.6%+1.0%
Q2 2019-6.9%-6.5%-15.1%
Q1 2019+3.0%-0.2%+17.8%
Q4 2018-11.2%-5.7%-1.1%
Q3 2018+7.2%+9.0%+1.1%
Q2 2018-15.8%-16.0%-3.8%
Q1 2018+9.5%+10.2%+15.7%
Q4 2017+3.9%+8.4%+11.0%
Q3 2017+9.3%+2.3%-3.3%
Q2 2017+5.8%+4.1%+4.4%
Q1 2017+4.3%-2.3%+1.0%
Q4 2016+3.8%+5.2%+7.8%
Q3 2016-2.5%+2.4%-4.2%
Q2 2016+10.9%+10.8%+6.6%
Q1 2016-1.7%
Q1 2015-1.7%
Q2 2014-6.3%
Q4 2015-6.3%
Q4 2013-6.3%
Q2 2015-6.3%
Q1 2014-6.3%
Q3 2014+23.4%
Q3 2015+23.4%
Q4 2014+23.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro